6 results about "Multivalent Vaccine" patented technology

The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

The application discloses a multivalent biological toxin antigen vaccine based on double receptor binding domain (RBD) assembly and a preparation method and application thereof. The application provides a multivalent biological toxin molecular antigen vaccine, and an active ingredient of the vaccine is a fusion protein formed by connecting an Hc protective antigen of biological toxin 1 and an Hc protective antigen of biological toxin 2 through a connecting peptide; the biological toxin 1 and the biological toxin 2 are two different biological toxins; and the biological toxin is selected from the following: tetanus toxin or other types of botulinum toxin (including types A, B and H) except type E. The application proves that different serotypes of botulinum toxin and tetanus toxin receptor binding domain Hc antigens are fused and assembled into a double Hc fusion antigen molecule by using genetic engineering and biosynthesis technology, and the double Hc fusion antigen molecule can generate strong protection against multiple biological toxins as a single subunit vaccine. Therefore, the Hc fusion antigen molecule vaccine of the application can generate protection against multiple different serotypes of biological toxin pathogens, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention and preventive treatment.

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

The invention belongs to the technical field of biology, and discloses a method for determining a multivalent antigen sequence of an anti-periodontitis red complex, which comprises the following steps: firstly, screening out key virulence factor antigens (FimA-II, RgpA, Msp and BspA) from three core pathogenic bacteria of the red complex: porphyromonas gingivalis, treponema denticola and fusisterone; then, independently cloning each antigen gene to a pUC57 cloning vector, constructing a single antigen recombinant plasmid, and avoiding intergene interference by designing a specific enzyme cutting site; and finally, through plasmid transformation, positive clone screening and double enzyme digestion verification, the plasmid quality is ensured. The obtained single antigen plasmid can be flexibly combined and used, is beneficial to subsequent multivalent vaccine development, and has the advantages of wide antigen coverage, high expression reliability, flexible construction strategy, easiness in industrialization and the like.

The present disclosure relates to a multivalent vaccine composition and its use in the protection against swine infections in a female pig and its progeny with a new scheme of administration.

The application discloses a gene modified non-toxic toxoid vaccine based on light chain-transmembrane region L-HN and receptor binding region Hc, and a preparation method and application thereof. The gene modified non-toxic novel toxoid vaccine molecule has two important protective antigen functional domains of a biological toxin, the N terminal of the vaccine molecule is the light chain-transmembrane region L-HN, and the C terminal is the receptor binding region Hc. The two protective antigen functional domains can be derived from the same biological toxin, can produce stronger protection than a single antigen, can produce strong complete protection at a low dose and a small number of immunization times, and can be used as a high-efficiency gene engineering toxoid vaccine to replace formaldehyde inactivated toxoid for biological toxin prevention. The two protective antigen functional domains can also be derived from different biological toxins, can protect against attacks of respective biological toxins, can produce protection against multiple different toxin biological agents, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention.